Trials / Completed
CompletedNCT02114931
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 467 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 81 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501 in adults with moderate to severe rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABP 501 | Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501 |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-04-15
- Last updated
- 2017-04-24
- Results posted
- 2017-04-24
Locations
77 sites across 11 countries: United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Romania, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02114931. Inclusion in this directory is not an endorsement.